Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Rectal Neoplasms 1Neoplasms 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × Immunoconjugates × Clear all
NCT01671813 2013-07-25

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡